<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    18376000
   </pmid>
   <datecreated>
    <year>
     2008
    </year>
    <month>
     04
    </month>
    <day>
     03
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2008
    </year>
    <month>
     04
    </month>
    <day>
     10
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2009
    </year>
    <month>
     02
    </month>
    <day>
     11
    </day>
   </daterevised>
   <article pubmodel="Print-Electronic">
    <journal>
     <issn issntype="Electronic">
      1533-4406
     </issn>
     <journalissue citedmedium="Internet">
      <volume>
       358
      </volume>
      <issue>
       14
      </issue>
      <pubdate>
       <year>
        2008
       </year>
       <month>
        Apr
       </month>
       <day>
        3
       </day>
      </pubdate>
     </journalissue>
     <title>
      The New England journal of medicine
     </title>
     <isoabbreviation>
      N. Engl. J. Med.
     </isoabbreviation>
    </journal>
    <articletitle>
     Simvastatin with or without ezetimibe in familial hypercholesterolemia.
    </articletitle>
    <pagination>
     <medlinepgn>
      1431-43
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND" nlmcategory="BACKGROUND">
      Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein (LDL) cholesterol when added to statin treatment. However, the effect of ezetimibe on the progression of atherosclerosis remains unknown.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      We conducted a double-blind, randomized, 24-month trial comparing the effects of daily therapy with 80 mg of simvastatin either with placebo or with 10 mg of ezetimibe in 720 patients with familial hypercholesterolemia. Patients underwent B-mode ultrasonography to assess the intima-media thickness of the walls of the carotid and femoral arteries. The primary outcome measure was the change in the mean carotid-artery intima-media thickness, which was defined as the average of the means of the far-wall intima-media thickness of the right and left common carotid arteries, carotid bulbs, and internal carotid arteries.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      The primary outcome, the mean (+/-SE) change in the carotid-artery intima-media thickness, was 0.0058+/-0.0037 mm in the simvastatin-only group and 0.0111+/-0.0038 mm in the simvastatin-plus-ezetimibe (combined-therapy) group (P=0.29). Secondary outcomes (consisting of other variables regarding the intima-media thickness of the carotid and femoral arteries) did not differ significantly between the two groups. At the end of the study, the mean (+/-SD) LDL cholesterol level was 192.7+/-60.3 mg per deciliter (4.98+/-1.56 mmol per liter) in the simvastatin group and 141.3+/-52.6 mg per deciliter (3.65+/-1.36 mmol per liter) in the combined-therapy group (a between-group difference of 16.5%, P&lt;0.01). The differences between the two groups in reductions in levels of triglycerides and C-reactive protein were 6.6% and 25.7%, respectively, with greater reductions in the combined-therapy group (P&lt;0.01 for both comparisons). Side-effect and safety profiles were similar in the two groups.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      In patients with familial hypercholesterolemia, combined therapy with ezetimibe and simvastatin did not result in a significant difference in changes in intima-media thickness, as compared with simvastatin alone, despite decreases in levels of LDL cholesterol and C-reactive protein. (ClinicalTrials.gov number, NCT00552097 [ClinicalTrials.gov].).
     </abstracttext>
     <copyrightinformation>
      Copyright 2008 Massachusetts Medical Society.
     </copyrightinformation>
    </abstract>
    <affiliation>
     Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands. j.j.kastelein@amc.uva.nl
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Kastelein
      </lastname>
      <forename>
       John J P
      </forename>
      <initials>
       JJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Akdim
      </lastname>
      <forename>
       Fatima
      </forename>
      <initials>
       F
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Stroes
      </lastname>
      <forename>
       Erik S G
      </forename>
      <initials>
       ES
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Zwinderman
      </lastname>
      <forename>
       Aeilko H
      </forename>
      <initials>
       AH
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Bots
      </lastname>
      <forename>
       Michiel L
      </forename>
      <initials>
       ML
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Stalenhoef
      </lastname>
      <forename>
       Anton F H
      </forename>
      <initials>
       AF
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Visseren
      </lastname>
      <forename>
       Frank L J
      </forename>
      <initials>
       FL
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Sijbrands
      </lastname>
      <forename>
       Eric J G
      </forename>
      <initials>
       EJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Trip
      </lastname>
      <forename>
       Mieke D
      </forename>
      <initials>
       MD
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Stein
      </lastname>
      <forename>
       Evan A
      </forename>
      <initials>
       EA
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Gaudet
      </lastname>
      <forename>
       Daniel
      </forename>
      <initials>
       D
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Duivenvoorden
      </lastname>
      <forename>
       Raphael
      </forename>
      <initials>
       R
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Veltri
      </lastname>
      <forename>
       Enrico P
      </forename>
      <initials>
       EP
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Marais
      </lastname>
      <forename>
       A David
      </forename>
      <initials>
       AD
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       de Groot
      </lastname>
      <forename>
       Eric
      </forename>
      <initials>
       E
      </initials>
     </author>
     <author validyn="Y">
      <collectivename>
       ENHANCE Investigators
      </collectivename>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <databanklist completeyn="Y">
     <databank>
      <databankname>
       ClinicalTrials.gov
      </databankname>
      <accessionnumberlist>
       <accessionnumber>
        NCT00552097
       </accessionnumber>
      </accessionnumberlist>
     </databank>
    </databanklist>
    <publicationtypelist>
     <publicationtype>
      Comparative Study
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Multicenter Study
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
    <articledate datetype="Electronic">
     <year>
      2008
     </year>
     <month>
      03
     </month>
     <day>
      30
     </day>
    </articledate>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     N Engl J Med
    </medlineta>
    <nlmuniqueid>
     0255562
    </nlmuniqueid>
    <issnlinking>
     0028-4793
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Anticholesteremic Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Azetidines
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Cholesterol, LDL
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Triglycerides
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      163222-33-1
     </registrynumber>
     <nameofsubstance>
      ezetimibe
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      57-88-5
     </registrynumber>
     <nameofsubstance>
      Cholesterol
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      79902-63-9
     </registrynumber>
     <nameofsubstance>
      Simvastatin
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="CommentIn">
     <refsource>
      N Engl J Med. 2008 Apr 3;358(14):1504-7
     </refsource>
     <pmid version="1">
      18376002
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      N Engl J Med. 2008 Apr 3;358(14):1507-8
     </refsource>
     <pmid version="1">
      18376001
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      N Engl J Med. 2008 Jul 31;359(5):530; author reply 532
     </refsource>
     <pmid version="1">
      18677796
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Kardiol Pol. 2008 May;66(5):597-8, discussion 598-9
     </refsource>
     <pmid version="1">
      18630396
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      N Engl J Med. 2008 Jul 31;359(5):530; author reply 532-3
     </refsource>
     <pmid version="1">
      18677797
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Prev Cardiol. 2008 Summer;11(3):177-8
     </refsource>
     <pmid version="1">
      18607155
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      N Engl J Med. 2008 Jul 31;359(5):529; author reply 532
     </refsource>
     <pmid version="1">
      18669434
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      N Engl J Med. 2008 Jul 31;359(5):529-30; author reply 532
     </refsource>
     <pmid version="1">
      18677795
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Curr Cardiol Rep. 2008 Nov;10(6):479-80
     </refsource>
     <pmid version="1">
      18950558
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Curr Atheroscler Rep. 2009 Jan;11(1):3-5, 8
     </refsource>
     <pmid version="1">
      19097303
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      Prev Cardiol. 2008 Summer;11(3):179-82
     </refsource>
     <pmid version="1">
      18612263
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="ErratumIn">
     <refsource>
      N Engl J Med. 2008 May 1;358(18):1977
     </refsource>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Anticholesteremic Agents
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Azetidines
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Carotid Arteries
     </descriptorname>
     <qualifiername majortopicyn="N">
      pathology
     </qualifiername>
     <qualifiername majortopicyn="N">
      ultrasonography
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Cholesterol
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Cholesterol, LDL
     </descriptorname>
     <qualifiername majortopicyn="Y">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Therapy, Combination
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Femoral Artery
     </descriptorname>
     <qualifiername majortopicyn="N">
      pathology
     </qualifiername>
     <qualifiername majortopicyn="N">
      ultrasonography
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Hyperlipoproteinemia Type II
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="N">
      pathology
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Simvastatin
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Outcome
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Triglycerides
     </descriptorname>
     <qualifiername majortopicyn="N">
      blood
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Tunica Intima
     </descriptorname>
     <qualifiername majortopicyn="N">
      pathology
     </qualifiername>
     <qualifiername majortopicyn="N">
      ultrasonography
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Tunica Media
     </descriptorname>
     <qualifiername majortopicyn="N">
      pathology
     </qualifiername>
     <qualifiername majortopicyn="N">
      ultrasonography
     </qualifiername>
    </meshheading>
   </meshheadinglist>
   <investigatorlist>
    <investigator validyn="Y">
     <lastname>
      Perez Jimenez
     </lastname>
     <forename>
      F
     </forename>
     <initials>
      F
     </initials>
    </investigator>
    <investigator validyn="Y">
     <lastname>
      Mata
     </lastname>
     <forename>
      P
     </forename>
     <initials>
      P
     </initials>
    </investigator>
    <investigator validyn="Y">
     <lastname>
      Habib
     </lastname>
     <forename>
      R
     </forename>
     <initials>
      R
     </initials>
    </investigator>
    <investigator validyn="Y">
     <lastname>
      Frohlich
     </lastname>
     <forename>
      J
     </forename>
     <initials>
      J
     </initials>
    </investigator>
    <investigator validyn="Y">
     <lastname>
      Gagne
     </lastname>
     <forename>
      C
     </forename>
     <initials>
      C
     </initials>
    </investigator>
    <investigator validyn="Y">
     <lastname>
      Ker
     </lastname>
     <forename>
      I
     </forename>
     <initials>
      I
     </initials>
    </investigator>
    <investigator validyn="Y">
     <lastname>
      Jacovides
     </lastname>
     <forename>
      A
     </forename>
     <initials>
      A
     </initials>
    </investigator>
    <investigator validyn="Y">
     <lastname>
      Madsen
     </lastname>
     <forename>
      E
     </forename>
     <initials>
      E
     </initials>
    </investigator>
    <investigator validyn="Y">
     <lastname>
      Ose
     </lastname>
     <forename>
      L
     </forename>
     <initials>
      L
     </initials>
    </investigator>
    <investigator validyn="Y">
     <lastname>
      Retterstoel
     </lastname>
     <forename>
      K
     </forename>
     <initials>
      K
     </initials>
    </investigator>
    <investigator validyn="Y">
     <lastname>
      Eriksson
     </lastname>
     <forename>
      M
     </forename>
     <initials>
      M
     </initials>
    </investigator>
    <investigator validyn="Y">
     <lastname>
      de Graaf
     </lastname>
     <forename>
      J
     </forename>
     <initials>
      J
     </initials>
    </investigator>
    <investigator validyn="Y">
     <lastname>
      Smit
     </lastname>
     <forename>
      A J
     </forename>
     <initials>
      AJ
     </initials>
    </investigator>
   </investigatorlist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="aheadofprint">
     <year>
      2008
     </year>
     <month>
      3
     </month>
     <day>
      30
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2008
     </year>
     <month>
      4
     </month>
     <day>
      1
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2008
     </year>
     <month>
      4
     </month>
     <day>
      11
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2008
     </year>
     <month>
      4
     </month>
     <day>
      1
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pii">
     NEJMoa0800742
    </articleid>
    <articleid idtype="doi">
     10.1056/NEJMoa0800742
    </articleid>
    <articleid idtype="pubmed">
     18376000
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

